Kymera Therapeutics Inc (NAS:KYMR)
$ 35.32 -0.69 (-1.92%) Market Cap: 2.17 Bil Enterprise Value: 1.78 Bil PE Ratio: 0 PB Ratio: 3.11 GF Score: 59/100

Kymera Therapeutics Inc at Bank of America Biotech SMID Cap Conference Transcript

Dec 07, 2022 / 08:30PM GMT
Release Date Price: $27.52 (+1.66%)
Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst

All right. Afternoon, everyone. My name is Geoff Meacham, I'm the Senior of Biopharma Analyst here at BofA, and welcome to the first day of our SMID Biotech Virtual Conference, and we're thrilled today to have Nello Mainolfi, who is CEO of Kymera Therapeutics. Nello, good to see you.

Nello Mainolfi
Kymera Therapeutics, Inc. - Co-Founder, President, CEO & Director

Thanks, Geoff. Thanks for the invite.

Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst

Yes, of course, yes. So before getting to questions, maybe you just want to give like a high-level overview and we can -- and go from there.

Nello Mainolfi
Kymera Therapeutics, Inc. - Co-Founder, President, CEO & Director

Yes. So welcome everybody. So the -- Kymera was founded about 6 years ago with the goal of taking a really powerful potentially transformative modality called targeted protein

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot